Updates are available Correction dated 2023-02-14
Click to view Correction: https://doi.org/10.1186/s13075-023-03005-x
-
Authors
Ueno, Masanobu
Miyagawa, Ippei
Miyazaki, Yusuke
Hanami, Kentaro
Fukuyo, Shunsuke
Kubo, Satoshi
Nakayamada, Shingo
Tanaka, Yoshiya http://orcid.org/0000-0002-0807-7139
- License Information
-
More Information
Article History
Received: 18 June 2022
Accepted: 20 October 2022
First Online: 27 October 2022
Change Date: 10 November 2022
Change Type: Update
Change Details: In affiliation 1, the country "Japan" was missing in the organization name. The article has been updated to rectify the error.
Change Date: 14 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13075-023-03005-x
Declarations
:
: Ethical approval was obtained from the University of Occupational and Environmental Health, Japan Ethics Committee (approval number #04-23), based on the Helsinki Declaration. Informed consent was obtained from all patients of the FIRST registry.
: Not applicable.
: Y. Tanaka has received speaking fees and/or honoraria from Behringer-Ingelheim, Eli Lilly, Abbvie, Gilead, AstraZeneca, Bristol-Myers, Chugai, Daiichi-Sankyo, Eisai, Pfizer, Mitsubishi-Tanabe, and GlaxoSmithKline and received research grants from Asahi-Kasei, Abbvie, Chugai, Eisai, Takeda, Daiichi-Sankyo, and Behringer-Ingelheim.S. Nakayamada has received consulting fees, speaking fees, and/or honoraria from Bristol-Myers, AstraZeneca, Pfizer, GlaxoSmithKline, Astellas, Asahi-kasei, Sanofi, Abbvie, Eisai, Chugai, Gilead, and Boehringer Ingelheim and has received research grants from Mitsubishi-Tanabe.Y. Miyazaki has received consulting fees, speaking fees, and/or honoraria from Eli Lilly and has received research grants from GlaxoSmithKline.
